
Odirlei Andre André Monticielo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7525547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 1 Diseases, 2018, 77, 1549-1557.</i>	0.784314	rgBT ₉ /Overlock
2	Association of the HLA-G 14Âbp polymorphism with systemic lupus erythematosus. Lupus, 2009, 18, 424-430.	1.6	83
3	The role of <i>Bsm</i> I and <i>Fok</i> I vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. Lupus, 2012, 21, 43-52.	1.6	77
4	The role of mannose-binding lectin in systemic lupus erythematosus. Clinical Rheumatology, 2008, 27, 413-419.	2.2	71
5	Pristane-induced lupus: considerations on this experimental model. Clinical Rheumatology, 2017, 36, 2403-2414.	2.2	67
6	Association of the <i>HLAâ€G</i> gene +3142C>G polymorphism with systemic lupus erythematosus. Tissue Antigens, 2011, 77, 540-545.	1.0	62
7	<i>TLR7/8/9</i> polymorphisms and their associations in systemic lupus erythematosus patients from Southern Brazil. Lupus, 2012, 21, 302-309.	1.6	61
8	Nail psoriasis: a review of the literature. Anais Brasileiros De Dermatologia, 2014, 89, 312-317.	1.1	59
9	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
10	Vitamin D and polymorphisms of VDR gene in patients with systemic lupus erythematosus. Clinical Rheumatology, 2012, 31, 1411-1421.	2.2	45
11	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. Lupus, 2015, 24, 788-795.	1.6	39
12	Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus. Clinical Rheumatology, 2017, 36, 89-95.	2.2	36
13	Osteopoikilosis: what does the rheumatologist must know about it?. Clinical Rheumatology, 2012, 31, 745-748.	2.2	34
14	SIRT1 promoter polymorphisms as clinical modifiers on systemic lupus erythematosus. Molecular Biology Reports, 2014, 41, 4233-4239.	2.3	34
15	Vitamin D and systemic lupus erythematosus: state of the art. Clinical Rheumatology, 2014, 33, 1033-1038.	2.2	33
16	Acquired Factor XI Inhibitor in Systemic Lupus Erythematosus—Case Report and Literature Review. Seminars in Arthritis and Rheumatism, 2009, 39, 61-65.	3.4	31
17	Diminished Expression of Complement Regulatory Proteins on Peripheral Blood Cells from Systemic Lupus Erythematosus Patients. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	29
18	Is Ultrasound a Better Target than Clinical Disease Activity Scores in Rheumatoid Arthritis with Fibromyalgia? A Case-Control Study. PLoS ONE, 2015, 10, e0118620.	2.5	29

Odirlei Andre André

#	Article	IF	CITATIONS
19	Vitamin D levels and cytokine profiles in patients with systemic lupus erythematosus. Lupus, 2015, 24, 1191-1197.	1.6	26
20	Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus, 2016, 25, 227-232.	1.6	26
21	Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. Anais Brasileiros De Dermatologia, 2015, 90, 314-319.	1.1	25
22	Predictors of hip fracture mortality at a general hospital in South Brazil: an unacceptable surgical delay. Clinics, 2014, 69, 253-258.	1.5	24
23	Endothelial nitric oxide synthase T-786C polymorphism in rheumatoid arthritis: association with extraarticular manifestations. Clinical Rheumatology, 2009, 28, 201-205.	2.2	23
24	Mannose-binding lectin gene polymorphisms in Brazilian patients with systemic lupus erythematosus. Lupus, 2010, 19, 280-287.	1.6	22
25	CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population. Lupus, 2013, 22, 802-809.	1.6	21
26	Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches. Seminars in Arthritis and Rheumatism, 2017, 46, 632-641.	3.4	21
27	Ficolin Gene Polymorphisms in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Annals of Human Genetics, 2016, 80, 1-6.	0.8	20
28	Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases. Vaccine, 2021, 39, 6454-6459.	3.8	18
29	Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. Autoimmunity, 2019, 52, 69-77.	2.6	16
30	Association of mannose-binding lectin 2 gene polymorphic variants with susceptibility and clinical progression in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2011, 29, 983-90.	0.8	16
31	Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia. Revista Brasileira De Reumatologia, 2017, 57, 403-411.	0.7	15
32	Urinary biomarkers for lupus nephritis: the role of the vascular cell adhesion molecule-1. Lupus, 2019, 28, 265-272.	1.6	15
33	Vitamin D receptor polymorphisms and expression profile in rheumatoid arthritis brazilian patients. Molecular Biology Reports, 2016, 43, 41-51.	2.3	14
34	Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus. Lupus, 2017, 26, 746-755.	1.6	14
35	Assessment of Mean Platelet Volume in Patients with Systemic Lupus Erythematosus. Open Rheumatology Journal, 2018, 12, 129-138.	0.2	14
36	Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis. BMC Rheumatology, 2020, 4, 67.	1.6	14

Odirlei Andre André

#	Article	IF	CITATIONS
37	Electroconvulsive therapy as a treatment for refractory neuropsychiatric lupus with catatonia: three case studies and literature review. Lupus, 2015, 24, 1327-1331.	1.6	13
38	Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis. International Journal of Clinical and Experimental Pathology, 2015, 8, 4600-13.	0.5	13
39	As decisões de tratamento com DMARD na artrite reumatoide parecem ser influenciadas pela fibromialgia. Revista Brasileira De Reumatologia, 2017, 57, 403-411.	0.8	12
40	Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil. Clinical Rheumatology, 2017, 36, 2005-2010.	2.2	12
41	Lupus animal models and neuropsychiatric implications. Clinical Rheumatology, 2021, 40, 2535-2545.	2.2	12
42	Vitamin D and Cytokine Profiles in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2020, 26, 289-294.	0.9	11
43	Concomitance of IgM and IgG anti-dsDNA Antibodies Does Not Appear to Associate to Active Lupus Nephritis. Open Rheumatology Journal, 2013, 7, 101-104.	0.2	10
44	Genetic polymorphisms of glutathione S-transferases and cytochrome P450 enzymes as susceptibility factors to systemic lupus erythematosus in southern Brazilian patients. Molecular Biology Reports, 2014, 41, 6167-6179.	2.3	9
45	Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients. Advances in Rheumatology, 2018, 58, 12.	1.7	7
46	Dualities of the vitamin D in systemic sclerosis: a systematic literature review. Advances in Rheumatology, 2021, 61, 34.	1.7	7
47	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. Lupus, 2021, 30, 1684-1695.	1.6	7
48	Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Advances in Rheumatology, 2022, 62, 3.	1.7	6
49	Higher IgG level correlated with vitamin D receptor in the hippocampus of a pristane-induced lupus model. Clinical Rheumatology, 2022, 41, 1859-1866.	2.2	6
50	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Advances in Rheumatology, 2021, 61, 60.	1.7	5
51	Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. Advances in Rheumatology, 2021, 61, 70.	1.7	5
52	Glu298Asp eNOS polymorphism is not associated with SLE. Lupus, 2009, 18, 448-451.	1.6	4
53	Wernicke's encephalopathy mimicking neuropsychiatric symptoms in patients with systemic lupus erythematosus: a report of three cases and literature review. Lupus, 2017, 26, 195-199.	1.6	4
54	T-cell specific upregulation of Sema4A as risk factor for autoimmunity in systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity, 2020, 53, 65-70.	2.6	4

Odirlei Andre André

#	Article	IF	CITATIONS
55	Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Advances in Rheumatology, 2020, 60, 29.	1.7	4
56	Nutritional aspects and cardiovascular risk in systemic lupus erythematosus. Revista Da Associação Médica Brasileira, 2021, 67, 656-660.	0.7	4
57	Non-criteria Antiphospholipid Antibodies: a narrative review. Revista Da Associação Médica Brasileira, 2020, 66, 1595-1601.	0.7	4
58	Morphological Parameters in Quadriceps Muscle Were Associated with Clinical Features and Muscle Strength of Women with Rheumatoid Arthritis: A Cross-Sectional Study. Diagnostics, 2021, 11, 2014.	2.6	3
59	Abdominal angiostrongyliasis: what does the rheumatologist must know about it?. International Journal of Rheumatic Diseases, 2009, 12, 267-271.	1.9	2
60	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
61	Pachydermoperiostosis associated with gastric neoplasia. Revista Da Associação Médica Brasileira, 2011, 57, 128-30.	0.7	1
62	Clinical diagnostic performance of different methods for the detection of antibodies to extractable nuclear antigens in connective tissue diseases: a cohort study. Clinical Laboratory, 2011, 57, 625-9.	0.5	1
63	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
64	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1
65	Esclerose sistêmica e nÃveis séricos elevados de organoclorado: uma associação possÃvel?. Revista Brasileira De Reumatologia, 2008, 48, .	0.8	0
66	FP128PODOCYTE-ASSOCIATED MESSENGER RNA PROFILES IN LUPUS NEPHRITIS: DOES SEVERITY OF THE HISTOLOGICAL LESIONS HAVE AN EFFECT ON THE INTENSITY OF PODOCYTE INJURY?. Nephrology Dialysis Transplantation, 2015, 30, iii109-iii110.	0.7	0
67	Anti-Müllerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review. Revista Brasileira De Reumatologia, 2015, 55, 363-367.	0.7	Ο
68	Pachydermoperiostosis associated with gastric neoplasia. Revista Da Associação Médica Brasileira, 2011, 57, 126-128.	0.7	0
69	<i>MBL2</i> gene polymorphisms and its relation to infection in Brazilian systemic lupus erythematosus patients: A 10-years follow-up study. Lupus, 2022, 31, 279-286.	1.6	Ο